Alpha 2.0
Login Register
» Articles » PMID: 32927932

Assessment of ST2 and Reg3a Levels in Patients with Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Overview
Journal Turk J Med Sci
Specialty General Medicine
Date 2020 Sep 15
PMID 32927932
Citations 3
Authors
Elifcan Aladag Karakulak
Haluk Demiroglu
Umit Yavuz Malkan
Umit Akman
Hakan Goker
Yahya Buyukasik
Affiliations
Soon will be listed here.
Abstract

Background/aim: Graft-versus-host disease (GVHD) is a crucial complication leading to significant morbidity and mortality allogeneic hematopoietic stem cell transplantation which occurs in approximately half of the transplant recipients. Suppression of tumorigenicity 2 (ST2) and regenerating islet-derived 3-alpha(Reg3a) might be important biomarkers to predict acute GVHD.

Materials And Methods: In the present study, blood samples were collected from 17 patients with acute GVHD and 12 control patients after allogeneic stem cell transplantation. ST2 and Reg3a were measured in plasma samples compared in patients with acute GVHD and the controls.

Results: Median age of the study population was 42 years (range 19–49). When compared to controls, the mean ST2 levels was significant higher in acute GVHD (9794 ng/dL vs. 2646 ng/dL, P = 0.008). Mean Reg3a level did not show significant difference between control and acute GVHD group (8848 ng/dL vs. 5632 ng/dL, respectively, P = 0.190).

Conclusion: The ST2 level might be used as a significant biomarker for predicting acute GVHD.

Citing Articles

Two machine learning-derived nomogram for predicting the occurrence and severity of acute graft-versus-host disease: a retrospective study based on serum biomarkers.

He Q, Li X, Fang Y, Kong F, Yu Z, Xie L Front Genet. 2024; 15:1421980.

PMID: 39582786 PMC: 11582066. DOI: 10.3389/fgene.2024.1421980.

ST2 and Reg3α: Can they predict aGvHD, steroid refractoriness and transplant-related mortality in pediatric patients after HSCT?.

Ozturk G, Bayrakoglu D, Haskologlu S, Baskin K, Deveci N, Ince E Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S129-S135.

PMID: 38658297 PMC: 11726067. DOI: 10.1016/j.htct.2024.02.026.

A single-center experience of haploidentical stem cell transplantation in hematological malignancies.

Malkan U, Goker H, Demiroglu H, Tekin F, Akdemir N, Aladag Karakulak E Turk J Med Sci. 2023; 53(1):352-359.

PMID: 36945951 PMC: 10388032. DOI: 10.55730/1300-0144.5591.

Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation.

Kwiecinska K, Strojny W, Bik-Multanowski M, Korostynski M, Piechota M, Balwierz W Cancer Control. 2022; 29:10732748211064776.

PMID: 35470705 PMC: 9052811. DOI: 10.1177/10732748211064776.

References
1.
Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View
2.
Ponce D, Hilden P, Mumaw C, Devlin S, Lubin M, Giralt S . High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2014; 125(1):199-205. PMC: 4281828. DOI: 10.1182/blood-2014-06-584789. View
3.
Ferrara J, Harris A, Greenson J, Braun T, Holler E, Teshima T . Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011; 118(25):6702-8. PMC: 3242723. DOI: 10.1182/blood-2011-08-375006. View
4.
Levine J, Logan B, Wu J, Alousi A, Ho V, Bolanos-Meade J . Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010; 16(12):1693-9. PMC: 2955996. DOI: 10.1016/j.bbmt.2010.05.019. View
5.
Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol. 2007; 137(2):87-98. DOI: 10.1111/j.1365-2141.2007.06533.x. View